Cooperative Huntington's Observational Research Trial - Full Text View

Sponsor:	HP Therapeutics Foundation
Collaborator:	Huntington Study Group
Information provided by:	HP Therapeutics Foundation
ClinicalTrials.gov Identifier:	NCT00313495

Purpose

The purpose of this study is to collect prospective data from individuals who are part of a Huntington Disease (HD) family, in order to relate phenotypes between individuals and families with each other and genetic factors in order to learn more about HD, develop potential treatments for HD, and to plan for future research studies of experimental drugs aimed at slowing or postponing the onset and progression of HD.

Condition
Huntington Disease

Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	Cooperative Huntington's Observational Research Trial

Resource links provided by NLM:

Genetics Home Reference related topics: chorea-acanthocytosis familial paroxysmal nonkinesigenic dyskinesia Huntington disease McLeod neuroacanthocytosis syndrome

MedlinePlus related topics: Huntington's Disease

U.S. FDA Resources

Further study details as provided by HP Therapeutics Foundation:

Biospecimen Retention: Samples With DNA

Blood, DNA and Urine

Estimated Enrollment:	5000
Study Start Date:	February 2006
Estimated Study Completion Date:	December 2020
Estimated Primary Completion Date:	December 2020 (Final data collection date for primary outcome measure)

Detailed Description:

COHORT (Cooperative Huntington Observational Research Trial) is a coordinated research effort by Huntington Study Group research centers worldwide to prospectively collect data from consenting individuals who are affected by Huntington's disease (HD) and who are part of an HD family. The systematically accrued data from annual prospective assessments will relate clinical characteristics (phenotypes) between families with genetic and environmental factors. The knowledge from these relationships will better inform us about the onset and progression of HD, help identify potential interventions for HD, and aid in planning research studies of experimental treatments aimed at slowing or postponing the onset of HD. The consented collection of biological samples will further provide research material and correlative data for scientists to identify biomarkers that parallel the development and progression of HD. Identification of biomarkers will in turn contribute to our understanding of HD and enhance the efficiency and power of disease-modifying therapeutic trials.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

An individual of any age that is affected by Huntington's disease
An individual 18 years of age or older, who has tested positive for the HD gene
An individual 18 years of age or older who is a parent, sibling or child of an individual affected by HD
An older adolescent 15 to 17 years of age, who has a parent affected by HD enrolled in COHORT, or a parent who has tested positive for the HD gene enrolled in COHORT (at select sites)
Grandparents and grandchildren of anyone participating in COHORT who fulfills the requirements of (the above) category (1) or (2)
HD family members who have no risk for HD due to no family history (spouses or caregivers)
HD family members who have undergone DNA testing and does not carry the genetic mutation responsible for HD.

Criteria

Inclusion Criteria:

(1) MANIFEST/PRE-MANIFEST HD: Individuals of any age who are affected by HD OR an individual 18 years or older who - has tested positive for the HD gene.
(2) INDIVIDUALS AT RISK: An individual 18 years or older who has not undergone DNA testing for the mutation responsible for HD and who is a first degree relative (parent, sibling, child) of an individual with Manifest or pre-manifest HD OR an older adolescent 15 to 17 years of age who has a parent with manifest HD or pre-manifest HD enrolled in COHORT.
(3) ADULTS AT SECONDARY RISK: An individual 18 years of age or older who has not undergone DNA testing for the mutation responsible for HD and is a grandparent or grandchild of an individual enrolled in COHORT who has manifest HD or pre-manifest HD
(4) CONTROL: A spouse or caregiver, 18 years of age or older, of an individual enrolled in COHORT who has manifest HD or pre-manifest HD
(5) ADULT GENE NEGATIVE: An individual, 18 years of age or older, with a family history of HD who has undergone DNA testing and does not carry the genetic mutation responsible for HD.

Exclusion Criteria:

(1) Anyone who does not fit the inclusion criteria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00313495

Contacts

Contact: Huntington Study Group

800-487-7671

Show 52 Study Locations

Sponsors and Collaborators

HP Therapeutics Foundation

Huntington Study Group

Investigators

Principal Investigator:

Ira Shoulson, MD

University of Rochester/Huntington Study Group

More Information

Additional Information:

The Huntington Study Group (HSG) is a non-profit group of physicians and other health care providers from medical centers in the U.S., Canada, Europe and Australia, experienced in the care of Huntington patients and dedicated to clinical research of HD. This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Ira Shoulson, MD/Principal Investigator, University of Rochester
ClinicalTrials.gov Identifier:	NCT00313495 History of Changes
Other Study ID Numbers:	COHORT
Study First Received:	April 10, 2006
Last Updated:	March 4, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by HP Therapeutics Foundation:

Huntington disease, observational, family members, biomarker

Additional relevant MeSH terms:

Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Dementia
Chorea
Dyskinesias

Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on February 12, 2012